相似文献
1
Amyloid, advanced glycation end products, and dialysis related arthropathy.
Ann Rheum Dis. 1998 Apr;57(4):193-5. doi: 10.1136/ard.57.4.193.
2
New aspects in the pathogenesis of dialysis-related amyloidosis: role of beta 2-microglobulin modified with advanced glycation end products in bone and joint destruction.
Nephrol Dial Transplant. 1996;11 Suppl 2:140-3. doi: 10.1093/ndt/11.supp2.140.
3
Beta2-microglobulin and renal bone disease.
Perit Dial Int. 1999;19 Suppl 2:S413-6.
4
Dialysis arthropathy.
Lancet. 1988;1(8575-6):27-8.
5
Beta 2-microglobulin-related amyloidosis: where do we stand?
Nephrol Dial Transplant. 1995;10(2):155-7.
6
Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis.
Nephrol Dial Transplant. 1996;11 Suppl 3:86-90. doi: 10.1093/ndt/11.supp3.86.
7
[Amyloidosis in patients undergoing long-term hemodialysis: elucidation of etiological mechanism and therapeutic stratigy].
Nihon Naika Gakkai Zasshi. 2005 Feb 20;94 Suppl:56-60. doi: 10.2169/naika.94.suppl_56.
8
Beta2-Microglobulin dialysis amyloid and its formation: role of 3-deoxyglucosone and advanced glycation end products.
Nephron. 1997;76(4):373-91. doi: 10.1159/000190218.
9
Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis.
Contrib Nephrol. 1995;112:52-64. doi: 10.1159/000424092.
10
Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis.
Miner Electrolyte Metab. 1999 Jan-Apr;25(1-2):114-7. doi: 10.1159/000057432.
本文引用的文献
1
Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis?
Kidney Int. 1997 Oct;52(4):1077-83. doi: 10.1038/ki.1997.431.
2
Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study.
Kidney Int. 1997 Jun;51(6):1928-32. doi: 10.1038/ki.1997.262.
3
High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis.
Am J Nephrol. 1996;16(6):484-8. doi: 10.1159/000169048.
4
Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group.
Kidney Int. 1996 Oct;50(4):1293-302. doi: 10.1038/ki.1996.441.
5
Polymerization of normal and intact beta 2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis.
Kidney Int. 1996 Oct;50(4):1262-7. doi: 10.1038/ki.1996.436.
6
Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation.
Kidney Int. 1996 Feb;49(2):506-11. doi: 10.1038/ki.1996.72.
7
Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology.
Kidney Int. 1996 Jul;50(1):282-9. doi: 10.1038/ki.1996.313.
8
New aspects in the pathogenesis of dialysis-related amyloidosis: role of beta 2-microglobulin modified with advanced glycation end products in bone and joint destruction.
Nephrol Dial Transplant. 1996;11 Suppl 2:140-3. doi: 10.1093/ndt/11.supp2.140.
9
Functional study of hands among patients dialysed for more than 10 years.
Nephrol Dial Transplant. 1993;8(4):347-51.
10
Is beta 2-microglobulin a mediator of bone disease?
Kidney Int. 1995 Jan;47(1):1-6. doi: 10.1038/ki.1995.1.
Zotero 插件